Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies
- Molecules. 2017 Aug 15;22(8):1356. doi: 10.3390/molecules22081356.
- 1. Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA. [email protected].
- 2. Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA. [email protected].
- 3. Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA. [email protected].
- 4. Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA. [email protected].
- 5. Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA. [email protected].
- 6. Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010, USA. [email protected].
Antisense Oligonucleotides (ASOs) conjugated to triantennary N-acetyl galactosamine (GalNAc) ligands represent an emerging approach to antisense therapy. Our current generation of GalNAc-ASO conjugates link the GalNAc to the 5'-terminus of the ASO. The conjugation reaction can be accomplished using solution-phase or solid-phase techniques. Here we show a direct comparison of a solution-phase and a solid-phase conjugation strategy. The solution-phase approach, using amine-pentafluorophenyl (PFP) ester coupling, is higher yielding and gives material of slightly higher purity, but requires several additional unit operations and longer production time. The solid-phase approach, using a protected GalNAc ligand phosphoramidite, is more expedient, but results in lower yield and purity. Both strategies efficiently deliver conjugated material in excellent purity.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Biochemical Assay ReagentsResearch Areas: Others